scispace - formally typeset
Search or ask a question
Institution

Ochsner Medical Center

HealthcareNew Orleans, Louisiana, United States
About: Ochsner Medical Center is a healthcare organization based out in New Orleans, Louisiana, United States. It is known for research contribution in the topics: Population & Heart failure. The organization has 980 authors who have published 1159 publications receiving 49961 citations. The organization is also known as: Ochsner Hospital & Ochsner Foundation Hospital.


Papers
More filters
Journal ArticleDOI
TL;DR: The clinical spectrum of GP infections and their effects on surgical airway complications (SAC) and bronchiolitis obliterans syndrome (BOS) following LT are described.
Abstract: Purpose. Gram-positive (GP) organisms are among the most common cause of infections in early postsurgical and immunocompromised populations. Patients recovering from lung transplantation (LT) are particularly susceptible owing to the physiologic stress imposed by surgery and induction with intense immunosuppression. Sites, types, and timing of GP infections following LT are not well documented. This report describes the clinical spectrum of GP infections and their effects on surgical airway complications (SAC) and bronchiolitis obliterans syndrome (BOS) following LT. Methods and materials. Data were collected from 202 patients undergoing 208 LT procedures at a single institution between November 1990 and November 2005. Data were retrospectively analyzed according to timing, location, and causative pathogen. Results. In the median follow-up period of 2.7 years (range, 0–13.6 years), 137 GP infections were confirmed in 72 patients. Sites of infection included respiratory tract (42%), blood (27%), skin, wound and catheter (21%), and other (10%). GP pathogens identified were Staphylococcus species (77%), Enterococcus species (12%), Streptococcus species (6%), Pneumococcus (4%), and Eubacterium lentum (1%). The likelihood of SAC and BOS was increased in lung allograft recipients with GP pneumonia as compared with those without (hazard ratio 2.1; 95% confidence interval=1.5–3.1). Conclusions. GP organisms were responsible for infections in 40% of lung allograft recipients and most commonly isolated from the respiratory tract and blood stream. Staphylococcal species were most frequently identified, 42% of which were methicillin-resistant Staphylococcus aureus (MRSA). Given the strong association of respiratory tract infections with the development of SAC and BOS, empiric antimicrobial strategies after LT should include agents directed against GP organisms, especially MRSA.

31 citations

Journal ArticleDOI
TL;DR: The data showed that patients with PBC were more likely than controls to have significant articular symptoms, a reduced ability to perform household chores, and the need for help with routine activities.

31 citations

Journal ArticleDOI
TL;DR: In this article, the authors show that early use of corticosteroids during immune checkpoint inhibitor (CPI) treatment significantly hinders the effectiveness of CPI, compared to no CS.
Abstract: Background Corticosteroids (CS) are the mainstay of immune-related adverse effect (irAE) management, as well as for other indications in cancer treatment. Previous studies evaluating whether CS affect immune checkpoint inhibitor (CPI) efficacy compared patients receiving CS versus no CS. However, there is a paucity of clinical data evaluating the timing of concomitant CS and CPI efficacy. Methods We retrospectively collected data from patients who received CS during CPI treatment at a single institution. Patients were in two cohorts based on timing of initiation of CS (≥2 months vs Results We identified 247 patients with metastatic cancer who received CS concurrently with CPIs. The median time on CS was 1.8 months. After adjusting for treatment type, tumor type, brain metastases, and irAEs, those treated with CS ≥2 months after starting CPI had a statistically significant longer PFS (HR=0.30, p Conclusion Our results suggest that early use of CS during CPI treatment significantly hinders CPI efficacy. This data needs to be validated prospectively. Future studies should focus on the immune mechanisms by which CSs affect T-cell function early in the CPI treatment course.

31 citations

Journal ArticleDOI
TL;DR: The diagnosis of the extra-axial chordoma is difficult but can be resolved by the detection of a strong brachyury expression and a cell line derived from the tumor showed rapid doubling-time, a strong expression of mesenchymal cell surface markers, a karyotype of diploid or hypotetraploid clones with numerous chromosome aberrations, and the ability to form colonies without attachment and to form tumors in immunocompromised mice.
Abstract: Background: Extra-axial chordomas are rare low-grade malignant tumors thought to arise from notochordal remnants in the extra-axial skeleton. Few studies have been done on this neoplasm because of its rarity. In addition, there is a lack of a good in vitro model on which to perform more characterization. Methods: We describe a twenty-eight-year-old man with a mass in the right scapula. Cytomorphology and immunohistochemistry, including brachyury staining, were used to formulate the final diagnosis. A fragment of the tumor was placed in culture, and cells obtained were injected subcutaneously in an immunocompromised mouse. From the tumor developed in mice, a cell line has been derived and characterized by fluorescence-activated cell-sorting analysis, karyotyping, clonogenicity, and cell and tumor growth curves. Results: Cytomorphology on the tumor showed nests of round cells with vacuoles and also physaliferous-like cells with uniform nuclei. Immunochemistry revealed a tumor positive for vimentin, moderately positive for S-100 and cytokeratin AE1/AE3, weakly positive for epithelial membrane antigen, and negative for p63 and cytokeratin (CK)-7. Further analysis revealed the tumor was diffusely and strongly positive for brachyury. The cell line derived from the tumor showed rapid doubling-time, a strong expression of mesenchymal cell surface markers, a karyotype of diploid or hypotetraploid clones with numerous chromosomal aberrations, and the ability to form colonies without attachment and to form tumors in immunocompromised mice. Conclusions: The diagnosis of the extra-axial chordoma is difficult but can be resolved by the detection of a strong brachyury expression. In addition, the derivation of a human extra-axial chordoma cell line could be a useful tool for the basic research of this rare neoplasm. Clinical Relevance: We describe the importance of brachyury staining in the diagnosis of this tumor. The extra-axial chordoma cell line (EACH-1) may also provide a new research tool to establish new ways of diagnosing and treating this rare malignancy.

31 citations

Journal ArticleDOI
01 Apr 2011-Urology
TL;DR: Persistent lower urinary tract symptoms comprise the highest frequency of complaints after colpocleisis, and this must be included in patient counseling in an aging patient population with expected increase in demand for pelvic floor reconstruction.

31 citations


Authors

Showing all 993 results

NameH-indexPapersCitations
Carl J. Lavie106113549318
Michael R. Jaff8244228891
Michael F. O'Rourke8145135355
Mandeep R. Mehra8064431939
Richard V. Milani8045423410
Christopher J. White7762125767
Bruce A. Reitz7433318457
Robert C. Bourge6927324397
Sana M. Al-Khatib6937717370
Hector O. Ventura6647816379
Andrew Mason6336015198
Aaron S. Dumont6038613020
Philip J. Kadowitz5537911951
David W. Dunn541958999
Lydia A. Bazzano5126713581
Network Information
Related Institutions (5)
Henry Ford Hospital
12.4K papers, 465.3K citations

80% related

Cleveland Clinic
79.3K papers, 3.4M citations

77% related

Cedars-Sinai Medical Center
26.4K papers, 1.2M citations

77% related

Vanderbilt University Medical Center
34.6K papers, 1.1M citations

76% related

Hospital of the University of Pennsylvania
14K papers, 459.9K citations

76% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20231
202223
2021120
2020117
2019102
201886